Saturday 17 October 2026 Export KAPA’s income statement to Excel — free account

Kairos Pharma, Ltd.

KAPA Healthcare Biotechnology

In the quarter to June 2026, EPS grew 25.0% and free cash flow fell 25.7%, each against the same quarter a year earlier.

0.60 0.07 −10.45%

Follow KAPA

Alert me

Market cap: $2.3M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
ROE Full definition →	+8 more TTM periods Free account	(92.07%)	(97.99%)	(93.84%)	(113.96%)
ROA Full definition →		(77.46%)	(88.51%)	(85.36%)	(104.32%)
ROIC Full definition →		(339.63%)	(346.52%)	(369.94%)	(322.91%)
Return on Tangible Assets Full definition →		(80.94%)	(104.99%)	(145.54%)	(199.55%)
Free Cash Flow per Share Full definition →		(1.44)	(1.31)	(1.25)	(1.30)
Free Cash Flow Full definition →		(4.16)	(3.44)	(3.76)	(3.97)
Other line items
Cash ROIC Full definition →		(29.10%)	(29.47%)	(39.14%)	(54.92%)
Accounts Payable Turnover Full definition →		0.00	0.00	0.00	0.00
Average Days of Payables Full definition →		0.00	0.00	0.00	0.00
Tax Rate Full definition →		0.00	0.00	0.00	0.00
Research and Development Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Operating CF/Net income Full definition →		0.82	0.63	0.64	0.68
Depreciation/Fixed assets Full definition →		0.00	0.00	0.00	0.00
Capex/Depreciation Full definition →		0.00	0.00	0.00	0.00
Revenue per Share Full definition →		0.00	0.00	0.00	0.00
Operating CF per Share Full definition →		(1.44)	(1.31)	(1.25)	(1.30)
Capex per Share Full definition →		0.00	0.00	0.00	0.00

Show all line items

Columns are period end dates